Skip to Content

'
Jeffrey E. Lee, M.D.

Present Title & Affiliation

Primary Appointment

Department Chair, Department of Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX
Professor, Department of Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX
Co-Director, Melanoma and Skin Cancer Research Program, The University of Texas MD Anderson Cancer Center, Houston, TX
Executive Director, Cancer Network, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX

Bio Statement

Dr. Jeffrey E. Lee is Professor and Chair of the Department of Surgical Oncology as well as Irving and Nadine Mansfield and Robert David Levitt Cancer Research Chair at the University of Texas MD Anderson Cancer Center in Houston, Texas. Dr. Lee received his AB from Dartmouth College and his MD from Stanford University School of Medicine. He completed a residency in surgery and a research fellowship in immunology at Stanford, followed by a clinical fellowship in surgical oncology at MD Anderson.  He joined the faculty at MD Anderson in 1993.  Dr. Lee’s clinical interests include the surgical management of patient with melanoma, pancreatic cancer and endocrine tumors.

Prior to assuming his role as Department Chair, Dr. Lee served for 17 years as Medical Director of the Ben Love/El Paso Corporation Melanoma and Skin Center. Dr. Lee is Co-Director of the Melanoma and Skin Cancer Research Program and recently completed a decade as Co-Director of MD Anderson’s NCI-sponsored Melanoma SPORE grant. A particular focus of his research is the role of genetics in melanoma progression. The overall goal of Dr. Lee’s research program has been to identify immune and inflammatory mechanisms controlling melanoma progression to help develop improved treatment strategies. 

Dr. Lee’s laboratory’s prior investigations have identified specific polymorphisms in human leukocyte antigen (HLA) class II as well as blood levels of IL-12, CRP and interferon gamma as independent markers of disease progression and prognosis in melanoma patients. His Melanoma Genetics and Blood Biomarker Program continues to analyze results related to a genome-wide investigation of more than 800,000 single-nucleotide polymorphisms (SNPs) in over 1800 melanoma patients to identify loci most strongly linked with melanoma progression, with plans to use this information to inform comprehensive biologic risk models of melanoma progression that incorporate clinical, histopathologic, serologic, and genetic information.

Office Address

The University of Texas MD Anderson Cancer Center
Department of Surgical Oncology
1400 Pressler Street
Unit Number: 1484
Houston, TX 77030
Room Number: FCT17.6042
Phone: 713-792-7218
Fax: 713-745-5068
Email: jelee@mdanderson.org

Education & Training

Degree-Granting Education

1984 Stanford University School of Medicine, Stanford, CA, MD, Medicine
1979 Dartmouth College, Hanover, NH, BA, Biochemistry

Postgraduate Training

1991-1993 Fellowship, Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, Charles M. Balch, M.D.
1990-1991 Chief Resident, General Surgery, Stanford University Medical Center, Stanford, CA, John A. Collins
7/1987-6/1989 Research Fellow, Immunology, Stanford University School of Medicine, Stanford, CA, Alan M. Krensky, M.D.
1984-1990 Resident, General Surgery, Stanford University Medical Center, Stanford, CA, John A. Collins, M.D.
1984-1985 Internship, General Surgery, Stanford University Medical Center, Stanford, CA, John A. Collins, M.D.

Selected Publications

Peer-Reviewed Original Research Articles

1. Fang S, Wang Y, Chun YS, Liu H, Ross MI, Gershenwald JE, Cormier JN, Royal RE, Lucci A, Schacherer CW, Reveille JD, Chen W, Sui D, Bassett RL, Wang LE, Wei Q, Amos CI, Lee JE. Association of common genetic polymorphisms with melanoma patient IL-12p40 blood levels, risk and outcomes. J Invest Dermatol. e-Pub 4/2015. PMID: 25848976.
2. Fang S, Wang Y, Sui D, Liu H, Ross MI, Gershenwald JE, Cormier JN, Royal RE, Lucci A, Schacherer CW, Gardner JM, Reveille JD, Bassett RL, Wang LE, Wei Q, Amos CI, Lee JE. C-reactive protein as a marker of melanoma progression. J Clin Oncol 33(12):1389-96, 4/2015. e-Pub 3/2015. PMCID: PMC4397281.
3. Fang S, Wang Y, Chun YS, Liu H, Ross MI, Gershenwald JE, Cormier JN, Royal RE, Lucci A, Schacherer CW, Reveille JD, Sui D, Bassett RL, Wang LE, Wei Q, Amos CI, Lee JE. The relationship between blood IL-12p40 level and melanoma progression. Int J Cancer 136(8):1874-80, 4/2015. e-Pub 9/2014. PMCID: PMC4323934.
4. Iles MM, Bishop DT, Taylor JC, Hayward NK, Brossard M, Cust AE, Dunning AM, Lee JE, Moses EK, Akslen LA, AMFS Investigators, Andresen PA, Avril MF, Azizi E, Scarrà GB, Brown KM, Debniak T, Elder DE, Friedman E, Ghiorzo P, Gillanders EM, Goldstein AM, Gruis NA, Hansson J, Harland M, Helsing P, Hocevar M, Höiom V, IBD investigators, Ingvar C, Kanetsky PA, Landi MT, Lang J, Lathrop GM, Lubinski J, Mackie RM, Martin NG, Molven A, Montgomery GW, Novakovic S, Olsson H, Puig S, Puig-Butille JA, QMEGA and QTWIN Investigators, Radford-Smith GL, Randerson-Moor J, SDH Study Group, van der Stoep N, van Doorn R, Whiteman DC, MacGregor S, Pooley KA, Ward SV, Mann GJ, Amos CI, Pharoah PD, Demenais F, Law MH, Newton Bishop JA, Barrett JH, GenoMEL Consortium. The effect on melanoma risk of genes previously associated with telomere length. J Natl Cancer Inst 106(10), 10/2014. e-Pub 9/2014. PMCID: PMC4196080.
5. Yin J, Liu H, Liu Z, Wang LE, Chen WV, Zhu D, Amos CI, Fang S, Lee JE, Wei Q. Genetic variants in Fanconi Anemia Pathway Genes BRca2 and FANCA Predict Melanoma Survival. J Invest Dermatol. e-Pub 9/2014. PMID: 25243787.
6. Iles MM, Law MH, Stacey SN, Han J, Fang S, Pfeiffer R, Harland M, Macgregor S, Taylor JC, Aben KK, Akslen LA, Avril MF, Azizi E, Bakker B, Benediktsdottir KR, Bergman W, Scarrà GB, Brown KM, Calista D, Chaudru V, Fargnoli MC, Cust AE, Demenais F, de Waal AC, Debniak T, Elder DE, Friedman E, Galan P, Ghiorzo P, Gillanders EM, Goldstein AM, Gruis NA, Hansson J, Helsing P, Hocevar M, Höiom V, Hopper JL, Ingvar C, Janssen M, Jenkins MA, Kanetsky PA, Kiemeney LA, Lang J, Lathrop GM, Leachman S, Lee JE, Lubinski J, Mackie RM, Mann GJ, Martin NG, Mayordomo JI, Molven A, Mulder S, Nagore E, Novakovic S, Okamoto I, Olafsson JH, Olsson H, Pehamberger H, Peris K, Grasa MP, Planelles D, Puig S, Puig-Butille JA, Randerson-Moor J, Requena C, Rivoltini L, Rodolfo M, Santinami M, Sigurgeirsson B, Snowden H, Song F, Sulem P, Thorisdottir K, Tuominen R, Van Belle P, van der Stoep N, van Rossum MM, Wei Q, Wendt J, Zelenika D, Zhang M, Landi MT, Thorleifsson G, Bishop DT, Amos CI, Hayward NK, Stefansson K, Bishop JA, Barrett JH, GenoMEL Consortium, Q-MEGA and AMFS Investigators. A variant in FTO shows association with melanoma risk not due to BMI. Nat Genet 45(4):428-32, 4/2013. e-Pub 3/2013. PMCID: PMC3640814.

Last updated: 9/14/2015